Journal of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회지)

Korean Society of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회)
권호 표지
DOI QR코드

DOI QR Code

Radiolabeled Benzamide Derivatives for Development of Malignant Melanoma Imaging Agents

  • Ayoung Pyo (Accelerator & RI Development Team, Korea Atomic Energy Research Institute) ;
  • Boreum Song (College of Pharmacy and Research Institute of Pharmaceutical Science, Gyeongsang National University) ;
  • Heejung Kim (Korea Radioisotope Center for Pharmaceuticals, Korea Institute of Radiological & Medical Sciences) ;
  • Dong-Yeon Kim (College of Pharmacy and Research Institute of Pharmaceutical Science, Gyeongsang National University)
  • Received : 2022.03.24
  • Accepted : 2022.06.24
  • Published : 2022.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Malignant melanoma has an aggressive nature and high metastatic potential that result in one of the highest cancer mortality rates. Over the past three decades, primary and metastatic melanoma incidence has rapidly increased. The recent advances in diagnostic technology have shown promise, but there is still an enormous need for specific detection methods to diagnose malignant melanoma. Positron emission tomography can visualize a particular biomarker of malignant melanoma and promise a noninvasive image of micrometastases. However, the development of PET radiopharmaceuticals remains necessary for diagnosing malignant melanoma by using positron emission tomography. In this review, the history and a general overview of PET radionuclide labeled benzamide derivatives, including their radiosynthesis, in vivo characterization, and evaluation, are provided as imaging agents for malignant melanoma.

Keywords

Acknowledgement

이 성과는 정부(과학기술정보통신부)의 재원으로 한국연구재단의 지원(NRF-2020R1C1C1012379 및 NRF-2021M2E7A3085685)과 산업통상자원부 및 산업기술평가관리원(KEIT) 연구비 지원(2001667)에 의한 연구이며, 다른 상업적 이해관계는 없음.

References

  1. Harries M., Malvehy J, Lebbe C, Heron L, Amelio J, Szabo Z, Schadendorf D. Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe. Eur J Cancer 2016;60:179-89. https://doi.org/10.1016/j.ejca.2016.01.011
  2. Henriques V, Martins T, Link W, Ferreira BL The emerging therapeutic landscape of advanced melanoma. Curr Pharm Des 2018;24:549-58. https://doi.org/10.2174/1381612824666180125093357
  3. Liu H, Liu S, Miao Z, Deng Z, Shen B, Hong X, Cheng, Z. Development of 18F-labeled picolinamide probes for PET imaging of malignant melanoma. J Med Chem 2013;56:895-901. https://doi.org/10.1021/jm301740k
  4. Prichard RS, Hill AD, Skehan SJ, 0'Higgins NJ. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 2002;89:389-96. https://doi.org/10.1046/j.0007-1323.2002.02059.x
  5. Ametamey SM, Honer M, Schubiger PA. Molecular imaging with PET. Chem Rev 2008;108: 1501-16. https://doi.org/10.1021/cr0782426
  6. Belhocine TZ, Scott AM, Even-Sapir E, Urbain JL, Essner R Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 2006;47:957-67.
  7. Choi EA, Gershenwald JE. Imaging studies in patients with melanoma. Surg Oneal Clin NAm 2007;16:403-30.
  8. Wei W, Ehlerding EB, Lan X, Luo Q, Cai W. PET and SPECT imaging of melanoma: the state of the art. Eur J Nucl Med Mol Imaging 2018;45: 132-50. https://doi.org/10.1007/s00259-017-3839-5
  9. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005;2:e70.
  10. Qin C, Liu H, Chen K, Hu X, Ma X, Lan X, Zhang Y, Cheng Z. Theranostics of malignant melanoma with 64CuCl2. J Nucl Med 2014;55:812-17. https://doi.org/10.2967/jnumed.113.133850
  11. Dimitrakopoulou-Strauss A, Strauss LG, Burger C. Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and 15O-water using compartment and noncompartment analysis. J Nucl Med 2001;42:248-56.
  12. Yang J, Xu J, Gonzalez R, Lindner T, Kratochwil C, Miao Y. 68Ga-DO-TA-GGNle-CycMSHhex targets the melanocortin-1 receptor for melanoma imaging. Sci Transl Med 2018; 10:eaau4445.
  13. Ren G, Miao Z, Liu H, Jiang L, Limpa-Amara N, Mahmood A, Gambhir SS, Cheng Z. Melanin-targeted preclinical PET imaging of melanoma metastasis. J Nucl Med 2009;50: 1692-99. https://doi.org/10.2967/jnumed.109.066175
  14. Link EM, Blower PJ, Costa DC, Lane DM, Lui D, Brown RS, Ell PJ, Spittle MF. Early detection of melanoma metastases with radioiodinated methylene blue. Eur J Nucl Med 1998; 25:1322-29. https://doi.org/10.1007/s002590050302
  15. Schroeder RL, Gerber JP. Chloroquine and hydroxychloroquine binding to melanin: Some possible consequences for pathologies. Toxicol Rep 2014;1:963-8. https://doi.org/10.1016/j.toxrep.2014.10.019
  16. Mars U, Larsson BS. Pheomelanin as a binding site for drugs and chemicals. Pigment Cell Res 1999; 12:266-74. https://doi.org/10.1111/j.1600-0749.1999.tb00760.x
  17. Garg S, Kothari K, Thopate SR, Doke AK, Garg PK. Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA): a novel potential PET probe to image melanoma tumors. Bioconjug Chem 2009;20: 583-90. https://doi.org/10.1021/bc8005094
  18. Kim HJ, Kim DY, Park JH, Yang SD, Hur MG, Min JJ, Yu KH. Synthesis and evaluation of a novel 68Ga-labeled DOTA-benzamide derivative for malignant melanoma imaging. Bioorg Med Chem Lett 2012;22:5288-92. https://doi.org/10.1016/j.bmcl.2012.06.043
  19. Kim HJ, Kim DY, Park JH, Yang SD, Hur MG, Min JJ, Yu KH. Synthesis and characterization of a 68Ga-labeled N-(2-diethylaminoethyl)benzamide derivative as potential PET probe for malignant melanoma. Bioorg Med Chem 2012;20:4915-20. https://doi.org/10.1016/j.bmc.2012.06.047
  20. Pyo A, Kim HS, Kim HS, Yun M, Kim DY, Min JJ. N-(2-(Dimethylamino)ethyl)-4-18F-fluorobenzamide: A novel molecular probe for highcontrast PET imaging of malignant melanoma. J Nucl Med 2019;60:924-9. https://doi.org/10.2967/jnumed.118.221416
  21. Pyo A, Kim DY, Kim H, Lim D, Kwon SY, Kang SR, Kim HS, Bom HS, Min JJ. Ultrasensitive detection of malignant melanoma using PET molecular imaging probes. Proc Natl Acad Sci U S A 2020;117:12991-9. https://doi.org/10.1073/pnas.1922313117
  22. Michelot JM, Moreau MF, Labarre PG, Madelmont JC, Veyre AJ, Papon JM, Parry DF, Bonafous JF, Boire JY, Desplanches GG, Bertrand SJ, Meyniel G. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med 1991;32:1573-80.
  23. Greguric I, Taylor SR, Denoyer D, Ballantyne P, Berghofer P, Roselt P, Pham TQ, Mattner F, Bourdier T, Neels OC, Dorow DS, Loe'h C, Hicks RJ, Katsifis A. Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance. J Med Chem 2009;52:5299-302. https://doi.org/10.1021/jm9008423
  24. Liu H, Liu S, Miao Z, Jiang H, Deng Z, Hong X, Cheng Z. A novel aliphatic 18F-labeled probe for PET imaging of melanoma. Mol Pharm 2013;10:3384-91. https://doi.org/10.1021/mp400225s
  25. Wu SY, Huang SP, Lo YC, Liu RS, Wang SJ, Lin WJ, Shen CC, Wang HE. Synthesis and preclinical characterization of [18F]FPBZA: a novel PET probe for melanoma. Biorned Res Int 2014;2014:912498.
  26. Chang CC, Chang CH, Lo YH, Lin MH, Shen CC, Liu RS, Wang HE, Chen CL. Preparation and characterization of a novel Al18F-NOTA-BZA conjugate for melanin-targeted imaging of malignant melanoma. Bioorg Med Chem Lett 2016;26:4133-9. https://doi.org/10.1016/j.bmcl.2016.06.022